Uterine Leiomyoma (Uterine Fibroids) - Pipeline Insight 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 21, 2018--The “Uterine Leiomyoma (Uterine Fibroids) - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Uterine Leiomyoma (Uterine Fibroids) - Pipeline Insight, 2018’ report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Uterine Leiomyoma (Uterine Fibroids) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Uterine Leiomyoma (Uterine Fibroids) Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Uterine Leiomyoma (Uterine Fibroids)
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive Products
Companies MentionedAbbVie Inc Addex Therapeutics Ltd Bayer AG BioSpecifics Technologies Corp Dongkook Pharmaceutical Co Ltd Kissei Pharmaceutical Co Ltd Laboratoire HRA Pharma Ogeda SA Repros Therapeutics Inc Takeda Pharmaceutical Company Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4vndsd/uterine_leiomyoma?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181221005295/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Women’s Health
INDUSTRY KEYWORD: WOMEN HEALTH CONSUMER GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/21/2018 09:49 AM/DISC: 12/21/2018 09:49 AM